Phellinus baumii Polyphenol: A Potential Therapeutic Candidate against Lung Cancer Cells

Xue Liu, Shiyao Cui, Caiyun Dan, Wenle Li, Hongqing Xie, Conghui Li, Liangen ShiInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study investigates Phellinus baumii polyphenol (PBP) as a potential lung cancer therapy. Researchers identified PBP's components, used network pharmacology to predict its anti-cancer mechanisms, and experimentally validated its ability to induce apoptosis and cell cycle arrest in lung cancer cells, with minimal toxicity to normal cells.

What Problem Does This Paper Address?

Lung cancer remains a significant global health challenge, and current treatments like surgery, radiotherapy, and chemotherapy often come with severe side effects. There's a continuous need for novel therapeutic strategies with fewer adverse effects. Natural products, particularly polyphenols known for their antioxidant and anti-inflammatory properties, have shown promise as anti-cancer agents. However, the specific therapeutic potential and underlying mechanisms of polyphenols from the medicinal fungus Phellinus baumii against lung cancer have not been fully elucidated. This paper aims to fill that gap by identifying PBP's active compounds and exploring its anti-lung cancer mechanisms.

Methods

The researchers employed a multi-pronged approach:

  • Chemical Characterization: UPLC-ESI-QTOF-MS was used to identify and characterize the chemical components of the Phellinus baumii polyphenol extract (PBP).
  • Network Pharmacology: This computational approach was used to predict potential therapeutic targets of PBP in lung cancer. It involved identifying PBP component targets and lung cancer targets, then finding their intersection to pinpoint key molecular players.
  • Molecular Docking: This technique was used to simulate the binding of key PBP components (osmundacetone and hispidin) to identified core targets (CASP3, PARP1, and TP53) to understand their interaction mechanisms.
  • In Vitro Experimental Validation:
    • Cytotoxicity Assays (CCK-8): To assess PBP's effect on the viability of lung cancer cells (A549) and normal cells (HEK293).
  • Flow Cytometry: Used to analyze cell apoptosis (Annexin V-FITC/PI staining), cell cycle distribution (PI staining), and reactive oxygen species (ROS) generation (DCF-DA staining).
  • Mitochondrial Membrane Potential (MMP) Assay: To evaluate changes in mitochondrial function using Mito-Tracker Red CMXRos.
  • Western Blotting: To examine the expression levels of key proteins involved in apoptosis and cell cycle regulation.

Datasets

  • Chemical Databases: DrugBank, TCMSP, PubChem, and ChemSpider were used for identifying PBP components and their targets.
  • Disease/Target Databases: OMIM, GeneCards, DisGeNET, and TTD were used to identify lung cancer-related targets.
  • Protein Structure Databases: PDB was used for obtaining 3D structures of core targets for molecular docking.

Key Insights and Ideas

  • PBP as a Multi-Target Agent: The study highlights that PBP doesn't act on a single target but rather influences multiple pathways involved in cancer progression, particularly apoptosis and cell cycle regulation.
  • Synergistic Action of Components: While PBP is a complex extract, the research points to specific compounds like osmundacetone and hispidin as key players, interacting with critical cancer-related proteins.
  • Targeting Cancer-Specific Pathways: PBP's effectiveness against cancer cells with minimal impact on normal cells suggests a degree of selectivity, a highly desirable trait for anti-cancer therapies.
  • Unveiling Traditional Medicine Mechanisms: The study provides a scientific basis for the traditional use of Phellinus baumii by elucidating its molecular mechanisms of action.

Key Results

  • PBP Composition: 17 chemical components of PBP were identified, with osmundacetone and hispidin identified as primary active components through molecular docking.
  • Target Identification: Network pharmacology identified 60 common targets between PBP components and lung cancer, with "pathway in cancer" being a significantly enriched pathway.
  • Cytotoxicity: PBP significantly inhibited the viability of A549 lung cancer cells (IC50 = 49.1 ± 0.5 µg/mL) with minimal toxicity to normal HEK293 cells.
  • Apoptosis Induction: PBP treatment led to a dose-dependent increase in apoptosis in A549 cells, evidenced by Annexin V-FITC staining and changes in apoptosis-related protein expression (e.g., increased Bax, cleaved PARP, active caspases).
  • MMP Depolarization: PBP caused a significant decrease in mitochondrial membrane potential in A549 cells, a hallmark of apoptosis.
  • Cell Cycle Arrest: PBP induced an S-phase arrest in A549 cells, altering the expression of key cell cycle regulators like CDK2, Cyclin A2, P21, and P53.
  • ROS Production: PBP treatment increased ROS generation in A549 cells, which is linked to apoptosis.

Limitations and Future Work

  • In Vivo Studies: The study was conducted in vitro. The authors acknowledge that in vivo studies are needed to confirm PBP's anti-tumor effects in a living organism and to investigate its efficacy and safety in animal models.
  • Pharmacokinetics and Dynamics: The absorption, distribution, metabolism, and excretion (ADME) properties of PBP and its active components were not investigated.
  • Mechanism Refinement: While key pathways like apoptosis and cell cycle arrest were identified, further research could delve deeper into the precise molecular interactions and signaling cascades involved.
  • Clinical Translation: The potential for PBP as an anti-tumor drug requires extensive preclinical and clinical trials.

The study concludes that PBP holds significant potential as a therapeutic candidate for lung cancer, paving the way for further drug development and research into the anti-tumor mechanisms of Phellinus baumii polyphenols.

Summary updated

Abstract

<i>Phellinus baumii</i>, a fungus that grows on mulberry trees and is used in traditional Chinese medicine, exerts therapeutic effects against various diseases, including cancer. Polyphenols, generally considered to be antioxidants, have antitumor and proapoptotic effects. In this study, we identified the composition of <i>Phellinus baumii</i> polyphenol (PBP) and characterized its 17 chemical components by UPLC-ESI-QTOF-MS. Furthermore, to clarify the potential mechanism of PBP against Lung Cancer Cells, network pharmacology and experimental verification were combined. Molecular docking elucidated the binding conformation and mechanism of the primary active components (Osmundacetone and hispidin) to the core targets CASP3, PARP1 and TP53. In addition, potential molecular mechanisms of PBP predicted by network pharmacology analysis were validated in vitro. PBP significantly inhibited the human lung cancer A549 cells and showed typical apoptotic characteristics, without significant cytotoxicity to normal human embryonic kidney (HEK293) cells. Analysis using flow cytometry and western blot indicated that PBP caused apoptosis, cell cycle arrest, reactive oxygen species (ROS) accumulation, and mitochondrial membrane potential (MMP) depression in A549 cells to exercise its antitumor effects. These results reveal that PBP has great potential for use as an active ingredient for antitumor therapy.
BibTeX
@article{liu2022phellinus,
  author = {Xue Liu and Shiyao Cui and Caiyun Dan and Wenle Li and Hongqing Xie and Conghui Li and Liangen Shi},
  title = {{Phellinus baumii Polyphenol: A Potential Therapeutic Candidate against Lung Cancer Cells}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms232416141},
}
Figure